AudioEye Appoints Yonatan Raz-Fridman as CBO to Enhance AI Retinal Diagnostics Growth
- AudioEye appoints Yonatan Raz-Fridman as Chief Business Officer to drive growth in AI-powered retinal diagnostics.
- AEYE-DS is the fastest-growing diabetic retinopathy screening technology, uniquely FDA-cleared for autonomous use.
- AEYE Health aims to revolutionize diabetic retinopathy care by enhancing screening efficiency and accessibility for patients globally.
AudioEye Appoints New Chief Business Officer to Accelerate Growth in AI-Powered Retinal Diagnostics
AEYE Health, a frontrunner in AI-driven retinal diagnostics, announces the appointment of Yonatan Raz-Fridman as Chief Business Officer. Known for his entrepreneurial success in founding and scaling technology firms such as Supersocial and Kano Computing, Raz-Fridman brings a wealth of experience to AEYE Health. In his new position, he is set to lead growth strategies and cultivate strategic partnerships aimed at expanding the reach of AEYE Health’s innovative technology. Central to this mission is the company’s flagship product, AEYE-DS, which provides diabetic retinopathy screenings to millions of patients globally, addressing a critical healthcare need.
The AEYE-DS system stands out as the fastest-growing diabetic retinopathy screening technology in the United States. It is uniquely FDA-cleared as a fully autonomous AI solution that can perform screenings without the need for physician interpretation. This capability allows for a quick, one-minute procedure that effectively bridges the care gap for diabetic eye exams. Moreover, it is reimbursable under CPT code 92229, making it financially accessible for healthcare providers. By enabling more frequent and efficient screenings, AEYE Health aims to revolutionize how diabetic retinopathy is diagnosed and managed, ensuring that patients receive timely care.
Zack Dvey-Aharon, Co-Founder and CEO of AEYE Health, expresses enthusiasm about Raz-Fridman’s appointment, citing his vision and proven track record in scaling transformative companies. Raz-Fridman himself recognizes the critical role he will play in AEYE Health’s growth trajectory, emphasizing the company’s commitment to leveraging autonomous AI to enhance point-of-care diagnostics. His leadership is expected to drive initiatives that will not only increase the adoption of AEYE-DS but also redefine the standard of care for diabetic patients, ultimately improving health outcomes on a global scale.
In addition to its innovative technology, AEYE Health is dedicated to making diagnostic screening practical and accessible. By focusing on the efficiency and accuracy of diabetic retinopathy screenings, the company aims to ensure that diabetic patients receive the necessary evaluations with minimal effort. This mission positions AEYE Health to make a significant impact on the healthcare landscape, offering a vital solution to a widespread condition that often goes undiagnosed.
As the healthcare industry increasingly looks toward AI solutions to enhance patient care, AEYE Health is poised to be a leader in this transformative movement, setting new benchmarks for accessibility and efficiency in diabetic retinopathy diagnosis.
